Title : A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance.

Pub. Date : 2020 Mar

PMID : 31923941






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 For the first time, MDM2-mediated p53 degradation was identified as a critical factor for developing acquired resistance of doxorubicin (DOX) in HepG2 tumor spheroids, which could be effectively reversed by MDM2 inhibitor MI-773, thereby improving anticancer effects. Doxorubicin tumor protein p53 Homo sapiens
2 For the first time, MDM2-mediated p53 degradation was identified as a critical factor for developing acquired resistance of doxorubicin (DOX) in HepG2 tumor spheroids, which could be effectively reversed by MDM2 inhibitor MI-773, thereby improving anticancer effects. Doxorubicin tumor protein p53 Homo sapiens
3 Therefore, a pH-sensitive liposomal formulation of DOX and MI-773 (LipD/M@CMCS) were developed for recovering p53-mediated DOX resistance in hepatocellular carcinoma. Doxorubicin tumor protein p53 Homo sapiens
4 Therefore, a pH-sensitive liposomal formulation of DOX and MI-773 (LipD/M@CMCS) were developed for recovering p53-mediated DOX resistance in hepatocellular carcinoma. Doxorubicin tumor protein p53 Homo sapiens